JP2003502388A5 - - Google Patents

Download PDF

Info

Publication number
JP2003502388A5
JP2003502388A5 JP2001504415A JP2001504415A JP2003502388A5 JP 2003502388 A5 JP2003502388 A5 JP 2003502388A5 JP 2001504415 A JP2001504415 A JP 2001504415A JP 2001504415 A JP2001504415 A JP 2001504415A JP 2003502388 A5 JP2003502388 A5 JP 2003502388A5
Authority
JP
Japan
Prior art keywords
mla
lipid
composition
antigen
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001504415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003502388A (ja
Filing date
Publication date
Priority claimed from US09/338,182 external-priority patent/US6491919B2/en
Application filed filed Critical
Publication of JP2003502388A publication Critical patent/JP2003502388A/ja
Publication of JP2003502388A5 publication Critical patent/JP2003502388A5/ja
Pending legal-status Critical Current

Links

JP2001504415A 1999-06-22 2000-06-14 モノホスホリルリピドａの水性免疫学的アジュバント組成物 Pending JP2003502388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/338,182 US6491919B2 (en) 1997-04-01 1999-06-22 Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US09/338,182 1999-06-22
PCT/US2000/016384 WO2000078353A2 (en) 1999-06-22 2000-06-14 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Publications (2)

Publication Number Publication Date
JP2003502388A JP2003502388A (ja) 2003-01-21
JP2003502388A5 true JP2003502388A5 (enExample) 2007-08-02

Family

ID=23323749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001504415A Pending JP2003502388A (ja) 1999-06-22 2000-06-14 モノホスホリルリピドａの水性免疫学的アジュバント組成物

Country Status (9)

Country Link
US (1) US6491919B2 (enExample)
EP (1) EP1194166B1 (enExample)
JP (1) JP2003502388A (enExample)
AT (1) ATE381344T1 (enExample)
AU (1) AU775942B2 (enExample)
CA (1) CA2376829A1 (enExample)
DE (1) DE60037514T2 (enExample)
ES (1) ES2296629T3 (enExample)
WO (1) WO2000078353A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
ATE395923T1 (de) * 2000-05-19 2008-06-15 Corixa Corp Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
JP2009522011A (ja) 2005-12-30 2009-06-11 Ｔｔｉ・エルビュー株式会社 活性物質を生体界面に送達するイオントフォレーシスシステム、装置及び方法
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
HUE032422T2 (en) * 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CA2725329C (en) * 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
BRPI1014031A2 (pt) * 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
US20150190501A1 (en) 2011-09-12 2015-07-09 Imperial Innovations Limited Methods and compositions for raising an immune response to hiv
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EA202192392A1 (ru) 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
CA3219794A1 (en) * 2021-05-27 2022-12-01 James M. Rolke Methods of treating or preventing allergies and chronic nasal congestion
WO2025058011A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 経鼻投与用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
NZ314058A (en) * 1993-01-22 2000-08-25 Sloan Kettering Inst Cancer Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse

Similar Documents

Publication Publication Date Title
JP5019494B2 (ja) モノホスホリルリピドａの水性免疫アジュバント組成物
JP2003502388A5 (enExample)
ES2296629T3 (es) Composiciones adyuvantes inmunologicas acuosas de monofosforil-lipido a.
KR100682154B1 (ko) 아쥬번트 조성물 및 그의 사용방법
JP4743928B2 (ja) 処方物
AU4094301A (en) Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
EP1150713B1 (en) Vaccine formulation comprising monoglycerides or fatty acids as adjuvant
WO2010033812A1 (en) Compositions and methods for treating hepatitis a.
WO2002102307A2 (en) Nucleoside vaccine adjuvants
AU2916302A (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid
HK1026613B (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
MXPA99009052A (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
FR2692149A1 (fr) Composition adjuvante de l'immunité humorale et à médiation cellulaire n'induisant pas de réponse vis-à-vis de déterminants auto-antigéniques.